ENDPOINTS NEWS19m
Re­cap­ping the End­points 100: The biotech in­dus­try braces it­self for Trump 2.0
End­points News has once again reached out to a lengthy ros­ter of biotech ex­ecs to take their pulse on what’s ahead for the ...
ENDPOINTS NEWS1h
Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set
Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...
ENDPOINTS NEWS1h
Keros halts parts of Phase 2 PAH tri­al due to safe­ty, stock tanks 70%
Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...
ENDPOINTS NEWS2h
Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture
Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...
ENDPOINTS NEWS2h
Pleno rais­es $25M for mul­ti­omics test­ing, names new CEO
Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...
ENDPOINTS NEWS2h
Cor­cept’s ALS drug fails to im­prove func­tion in Phase 2 study
Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...
ENDPOINTS NEWS19h
Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...
ENDPOINTS NEWS23h
Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies
Companies Beam Therapeutics and Prime Medicines presented research on reducing chemotherapy in gene therapy conditioning, ...
ENDPOINTS NEWS19h
NIH halts en­roll­ment in tri­al for SIGA's mpox an­tivi­ral af­ter dis­ap­point­ing da­ta
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...
ENDPOINTS NEWS20h
Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...
ENDPOINTS NEWS23h
Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023
Ace­lyrin is of­fi­cial­ly end­ing de­vel­op­ment of an ex­per­i­men­tal med­i­cine it re­ferred to as a “ di­a­mond in the ...
ENDPOINTS NEWS22h
Re­lay Ther­a­peu­tics plans piv­otal tri­al in sec­ond-line breast can­cer for 2025
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα ...